By Medical News Desk
In a decisive move to standardize the next generation of COVID-19 boosters, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 8 to 0, with one abstention, to recommend the monovalent XFG variant as the target for the 2026-2027 respiratory virus season. The decision marks a significant milestone in the ongoing effort to align vaccine composition with the rapidly evolving landscape of SARS-CoV-2 sub-lineages.
The Core Decision: Why XFG?
The committee’s recommendation reflects a strategic consensus on the current dominant circulating strains in the United States. The XFG variant has established itself as the most prevalent strain, and experts argue that focusing the upcoming vaccine on this lineage provides the most robust defense against the JN.1 family of variants.
Dr. Anna Durbin of the Johns Hopkins Bloomberg School of Public Health, who voted in favor of the selection, emphasized the necessity of balancing current prevalence with long-term surveillance. “The XFG variant is the most common variant in the U.S. right now,” Durbin noted. “Looking at the other JN.1 variants that may be emerging, I am confident that targeting XFG is the right way to go. The immunogenicity of these vaccines looks promising, and I felt very comfortable voting yes.”
The selection also reflects a pragmatic approach to vaccine manufacturing. Dr. Stanley Perlman of the University of Iowa, who chaired the committee, noted that while the World Health Organization (WHO) had recommended the LP.8.1 strain—which is currently targeted by existing Moderna and Pfizer formulations—the XFG variant offers a comparable and strategically viable alternative for the U.S. market.
"I was swayed by the fact that Sanofi, through its acquisition of Novavax’s protein subunit technology, is positioned to produce an XFG vaccine," Perlman explained. "Given that LP.8.1 and XFG are highly similar, adopting XFG allows for broader manufacturing capabilities across the major platforms, including mRNA and protein-based options."
A Minority Dissent: The Question of Breadth
Despite the overwhelming vote, the committee’s proceedings were marked by a nuanced debate regarding the potential risks of ignoring emerging lineages, specifically the BA.3.2 variant, colloquially referred to as "cicada."
Dr. Hana El Sahly of Baylor College of Medicine, who cast the lone abstention, expressed concern that the committee might be prioritizing short-term gains at the expense of future-proofing. She argued that the data showed the XFG vaccine to be effectively interchangeable with LP.8.1, leaving a gap in coverage for variants that have shown concerning growth patterns in other parts of the world.
"We might be missing the opportunity to expand the breadth of our response to the NB.1.8.1 and BA.3.2 variants," El Sahly stated. She highlighted that BA.3.2 has already demonstrated the ability to become the dominant strain in Germany and South Africa. "I would be concerned if BA.3.2 starts to acquire additional mutations and increases in frequency over the next few months. While XFG is quite robust for the JN.1 family, it may not be sufficient for BA.3.2."
El Sahly further pointed out that children remain "engines of transmission" for respiratory viruses, and failing to account for shifting variant dynamics could lead to a resurgence in pediatric cases.
Chronology of the Meeting and Data Review
The meeting was structured to provide a comprehensive look at the state of the pandemic as it enters its seventh year. The day began with presentations from the Centers for Disease Control and Prevention (CDC), aimed at establishing a baseline for viral evolution and vaccine effectiveness (VE).
The Surveillance Gap
A recurring theme throughout the day was the inadequacy of current epidemiologic and genomic surveillance. Dr. Flor Munoz-Rivas, also of Baylor College of Medicine, urged the agency to improve its data collection infrastructure. "The stronger our systems are, the better we’ll be in position to make decisions for variants that are going to continue to emerge," Munoz-Rivas noted. The committee acknowledged that without high-fidelity, real-time data, selecting a "perfect" strain remains a best-guess endeavor.
The "Suppressed" Data Controversy
The committee discussion occurred against a backdrop of recent controversy regarding CDC transparency. The meeting included a review of interim vaccine effectiveness data that had been the subject of recent scrutiny after it was revealed that top-level CDC leadership had initially suppressed the publication of specific findings. Jeremy Faust, MD, editor-in-chief of MedPage Today, played a pivotal role in bringing these suppressed documents to public light, ensuring the committee had the full picture of vaccine performance before voting.
Presentation of Effectiveness Data
Dr. Amanda Payne of the CDC’s National Center for Immunization and Respiratory Diseases (NCIRD) presented the agency’s analysis of its VISION system. The data provided a clear, if sobering, view of vaccine performance for the 2025-2026 season:
- Emergency Department/Urgent Care: 49% effectiveness.
- Hospitalization: 58% effectiveness.
- Critical Illness: 49% effectiveness.
Payne noted that these figures remain consistent through the first six months post-vaccination, though effectiveness is noticeably higher—often peaking—in the first 60 days following the shot.
Clinical Implications and Future Challenges
The data presented by manufacturers—Moderna, Pfizer, and Sanofi—demonstrated that while XFG-based vaccines provide high levels of neutralizing antibodies against the JN.1 family, they offer more limited neutralization against BA.3.2.
When companies tested candidates specifically designed to target BA.3.2, they saw improved coverage for that lineage, but at a distinct cost: a reduction in the neutralizing breadth against the JN.1 variants. This "tug-of-war" between variants illustrates the inherent difficulty in designing a universal or even a highly effective seasonal COVID-19 vaccine.
Timing the Surge
The committee also wrestled with the timing of the annual vaccine campaign. Traditionally, the FDA targets a late spring/early summer selection process. However, the epidemiology of COVID-19 has diverged from that of influenza. While flu typically peaks in the winter, COVID-19 continues to exhibit multi-peak behavior, with significant surges in late summer, early autumn, and winter. The committee discussed whether moving the strain selection process would allow for a more precise match, though no formal policy change was enacted.
Hospitalization Trends
Despite the ongoing challenges, there is cause for optimism. Dr. Natalie Thornburg, chief of the laboratory branch within NCIRD’s COVID division, reported that hospitalization rates for the 2025-2026 season are the lowest since the pandemic began and have shown a steady, year-over-year decline.
The burden of disease remains heavily skewed toward the elderly and the very young. Hospitalization rates remain highest in patients 75 years and older, followed by infants under six months of age. Thornburg emphasized that, unlike older adults, the majority of hospitalized infants (76%) had no underlying medical conditions, underscoring the vulnerability of the youngest population to current circulating strains.
Conclusion: Looking Ahead to 2026
The recommendation of the XFG variant represents a consensus aimed at maintaining the momentum of declining hospitalizations while leveraging the most stable, mass-producible technology available. By aligning the U.S. vaccine strategy with a variant that provides strong protection against the dominant JN.1 family, the FDA is banking on a "best-fit" scenario to manage the upcoming winter surge.
However, the warnings issued by committee members regarding BA.3.2 and the systemic need for more robust surveillance suggest that the work of the VRBPAC is far from over. As SARS-CoV-2 continues to mutate, the balance between providing broad, durable protection and responding to rapidly shifting variant landscapes remains the primary challenge for global public health authorities. For now, the focus shifts to the manufacturers, who must begin the gargantuan task of scaling production for the 2026-2027 season based on this latest regulatory mandate.
